Pink.Pr
PINK.PR operates in the drug retailing segment, primarily generating revenue through the sale of pharmaceutical products and related services.
Business. PINK.PR operates in the drug retailing segment, primarily generating revenue through the sale of pharmaceutical products and related services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PINK.PR operates in the drug retailing segment, primarily generating revenue through the sale of pharmaceutical products and related services.
PINK.PR exhibits a weak capital structure, with a negative total equity of -93.98 million CZK and a debt-to-equity ratio of -0.52, indicating a high reliance on debt financing. The company's liquidity position is further strained by a current ratio of 0.46, suggesting limited ability to meet short-term obligations. Additionally, the company reported negative operating cash flow of -44.99 million CZK and free cash flow of -57.70 million CZK, highlighting ongoing cash flow challenges.
Profitability metrics for PINK.PR are concerning, with a return on equity of 1.34 and a return on assets of -0.53, both significantly below industry norms. The company's operating income was -101.24 million CZK, and net income was -125.62 million CZK, indicating a substantial decline in profitability. These figures suggest that the company is struggling to generate returns that meet the expectations of its stakeholders.
Geographically and segment-wise, PINK.PR's revenue concentration is not explicitly detailed in the available data. However, the company's primary business activity is in the drug retailing sector, which is subject to regulatory and competitive pressures. The lack of detailed segment data limits the ability to assess the company's exposure to different markets or product lines.
The company's growth trajectory is negative, with a reported revenue of 1.304 billion CZK, but no specific growth rates or future projections are provided in the available data. The absence of positive revenue growth and the presence of negative operating and net income figures indicate a challenging business environment for PINK.PR.
Risk factors for PINK.PR include a medium liquidity risk, as evidenced by the negative net cash position after subtracting total debt. The company also faces potential dilution risks, although the current level is assessed as low. The negative equity and high debt levels suggest that the company may need to raise additional capital, which could lead to further dilution of existing shareholders.
Recent events and filings for PINK.PR are not detailed in the available data. However, the company's financial performance and liquidity position suggest that it may be under pressure to address its financial challenges through strategic initiatives or capital restructuring.
- PINK.PR is experiencing significant financial distress, with negative equity and operating cash flow.
- The company's profitability metrics are well below industry norms, indicating poor performance.
- Liquidity constraints and high debt levels pose a risk to the company's short-term solvency.
- The lack of detailed segment and geographic data limits the ability to assess diversification and exposure.
- The company's growth trajectory is negative, with no clear path to improvement in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PINK.PR Market data — financials · 2026-05-28